Written answers
Wednesday, 15 June 2022
Department of Health
Medicinal Products
Colm Burke (Cork North Central, Fine Gael)
Link to this: Individually | In context | Oireachtas source
197. To ask the Minister for Health the work that his Department and the HSE are undertaking in order that 35 children with cystic fibrosis whose age and genotype were not included in the initial deal with the drug manufacturer will now be included to provide access to the life changing medication kaftrio; and if he will make a statement on the matter. [31066/22]
Steven Matthews (Wicklow, Green Party)
Link to this: Individually | In context | Oireachtas source
211. To ask the Minister for Health if his attention has been drawn to the campaign by the families of 35 children with cystic fibrosis seeking access to a medication called kaftrio that had been promised to these families by their medical teams previously; and if he will make a statement on the matter. [31093/22]
Duncan Smith (Dublin Fingal, Labour)
Link to this: Individually | In context | Oireachtas source
216. To ask the Minister for Health the reason there are 35 children in Ireland that have cystic fibrosis are excluded from the pipeline deal for the drug kaftrio; and if he will make a statement on the matter. [31155/22]
Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
I propose to take Questions Nos. 197, 211 and 216 together.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
No comments